| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
exo-BCN-NHS carbonate targets azide-functionalized molecules through the BCN group, which undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) reactions. The NHS carbonate group targets primary amines (-NH₂) on proteins, antibodies, and other biomolecules. The compound does not target a specific protein or enzyme but rather serves as a bifunctional linker that connects azide-containing molecules to amine-containing molecules. The BCN group enables copper-free click chemistry, which is bioorthogonal and compatible with biological systems.
|
|---|---|
| ln Vitro |
The in vitro activity of exo-BCN-NHS carbonate is its function as a click chemistry reagent for bioconjugation. The BCN group undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. The NHS carbonate group reacts with primary amines to form stable carbamate linkages. This enables the creation of stable bioconjugates, antibody-drug conjugates (ADCs), and functionalized surfaces. The reaction offers high specificity, fast kinetics, and minimal perturbation of biological systems. The compound is used in biopharmaceutical, diagnostic, and imaging applications.
|
| ln Vivo |
exo-BCN-NHS carbonate is not used as a therapeutic agent. Its in vivo utility is limited to research applications involving the preparation of bioconjugates for imaging, drug delivery, and diagnostic development. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro conjugation assays for exo-BCN-NHS carbonate involve incubating the NHS carbonate with amine-containing biomolecules in appropriate buffer conditions (typically pH 7-9) to form stable carbamate linkages. The BCN-functionalized product is then reacted with azide-containing molecules via SPAAC click chemistry. The reaction is copper-free and proceeds rapidly under physiological conditions. The formation of the conjugate can be confirmed by SDS-PAGE, mass spectrometry, or other analytical methods.
|
| Cell Assay |
For in vitro cellular experiments, exo-BCN-NHS carbonate is used to prepare bioconjugates that are then added to cell culture medium for incubation with target cells. For example, a protein conjugated to a fluorescent dye or drug via this linker could be used to study cellular uptake, localization, or function. The bioorthogonal nature of the SPAAC reaction ensures minimal interference with cellular processes.
|
| Animal Protocol |
In vivo animal experiments with exo-BCN-NHS carbonate are not typically performed with the compound itself. However, bioconjugates prepared using this linker can be administered to animal models for studying drug delivery, imaging, or protein function in vivo. The SPAAC reaction is compatible with in vivo applications due to its bioorthogonality and fast kinetics.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of exo-BCN-NHS carbonate have not been characterized, as the compound is a research-use click chemistry reagent rather than a drug candidate. The compound has a molecular weight of 291.30 g/mol and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
The compound is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| Additional Infomation |
exo-BCN-NHS carbonate (CAS#: 1493802-77-9) is a click chemistry reagent containing a BCN group for SPAAC reactions with azide-containing compounds. It is ideal for constructing stable bioconjugates, ADCs, or functionalized surfaces in biopharmaceutical, diagnostic, and imaging applications. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C15H17NO5
|
|---|---|
| Molecular Weight |
291.30
|
| Exact Mass |
291.11
|
| CAS # |
1493802-77-9
|
| PubChem CID |
75412386
|
| Appearance |
White to off-white solid powder
|
| Density |
1.35±0.1 g/cm3(Predicted)
|
| Boiling Point |
412.8±28.0 °C(Predicted)
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
509
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O(C(=O)ON1C(CCC1=O)=O)CC1[C@@H]2CCC#CCC[C@@H]21
|
| InChi Key |
SKTDJYHCSCYLQU-FOSCPWQOSA-N
|
| InChi Code |
InChI=1S/C15H17NO5/c17-13-7-8-14(18)16(13)21-15(19)20-9-12-10-5-3-1-2-4-6-11(10)12/h10-12H,3-9H2/t10-,11+,12?
|
| Chemical Name |
[(1S,8R)-9-bicyclo[6.1.0]non-4-ynyl]methyl (2,5-dioxopyrrolidin-1-yl) carbonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4329 mL | 17.1644 mL | 34.3289 mL | |
| 5 mM | 0.6866 mL | 3.4329 mL | 6.8658 mL | |
| 10 mM | 0.3433 mL | 1.7164 mL | 3.4329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
